Anlotinib is a new, orally administered tyrosine kinase inhibitor that targets vascular
endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet …

Antiangiogenic drugs targeting the VEGF pathway have slowed metastatic disease
progression in some patients, leading to progression-free survival (PFS) and overall survival …

The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the
clinical management of patients with clear cell and non–clear cell renal carcinoma. These …

Background Anlotinib is a novel multi-target tyrosine kinase inhibitor that is designed to
primarily inhibit VEGFR2/3, FGFR1-4, PDGFR α/β, c-Kit, and Ret. We aimed to evaluate the …

Background Sunitinib and everolimus are standard first-line and second-line therapies,
respectively, in clear cell renal cell carcinoma (ccRCC). Objective To conduct a randomized …

Purpose Foretinib is an oral multikinase inhibitor targeting MET, VEGF, RON, AXL, and TIE-2
receptors. Activating mutations or amplifications in MET have been described in patients …

Background Adjuvant sunitinib significantly improved disease-free survival (DFS) versus
placebo in patients with locoregional renal cell carcinoma (RCC) at high risk of recurrence …

Background Hypertension (HTN) is an on-target effect of the vascular endothelial growth
factor pathway inhibitor, sunitinib. We evaluated the association of sunitinib-induced HTN …

Diarrhea is one of the main drawbacks for cancer patients. Possible etiologies could be
radiotherapy, chemotherapeutic agents, decreased physical performance, graft versus host …

There has been a rapid emergence of numerous targeted agents in the oncology community
in the last decade. This exciting paradigm shift in drug development lends promise for the …